HMTC yields 49.50% · ABBV yields 3.06%● Live data
📍 HMTC pulled ahead of the other in Year 1
Combined, HMTC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HMTC + ABBV for your $10,000?
Homasote Company manufactures and sells building and industrial products for the construction and manufacturing industries in the United States. The company operates through two divisions, Millboard and Industrial. The Millboard division provides wall and floor sound insulation products, roof and floor deckings, concrete expansion joints and forming boards, and finished interior panels. The Industrial division offers various shapes and coated strips for product separation and breakage reduction that protects customer's products during interplant transport primarily for use in glass, paper, and metal industries, as well as provides packaging products to end-users, appliance manufacturers, and office furniture makers. The company's products are applied in various applications that include sound control, basement and concrete slab conversions, cathedral ceilings, fire-rated products, concrete forming, decorative/tackable panels, floors, floor and surface protection products, hobbies, house and workshops, ice rink conversions, roofs and ceilings, shock absorptions, thermal insulations, and walls, as well as construction and renovation of multi-family dwellings, commercial office buildings, educational facilities, single-family dwellings, and retail establishments. It serves building material wholesalers and contractors, and industrial manufacturers. The company also exports its products to Canada and internationally. Homasote Company was founded in 1909 and is based in West Trenton, New Jersey.
Full HMTC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.